Market closedNon-fractional
Travere Therapeutics/TVTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Travere Therapeutics
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.
Ticker
TVTX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
San Diego, United States
Employees
380
Website
www.travere.com
TVTX Metrics
BasicAdvanced
$744M
Market cap
-
P/E ratio
-$2.11
EPS
0.78
Beta
-
Dividend rate
Price and volume
Market cap
$744M
Beta
0.78
Financial strength
Current ratio
2.777
Quick ratio
2.699
Long term debt to equity
538.645
Total debt to equity
545.444
Interest coverage (TTM)
-37.07%
Management effectiveness
Return on assets (TTM)
-35.53%
Return on equity (TTM)
-315.89%
Valuation
Price to revenue (TTM)
4.8
Price to book
10.06
Price to tangible book (TTM)
-27.47
Price to free cash flow (TTM)
-2.207
Growth
Revenue change (TTM)
69.52%
Earnings per share change (TTM)
-52.59%
3-year revenue growth (CAGR)
-7.69%
3-year earnings per share growth (CAGR)
-21.84%
What the Analysts think about TVTX
Analyst Ratings
Majority rating from 16 analysts.
TVTX Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$41M
-8.22%
Net income
-$136M
50.94%
Profit margin
-329.29%
64.46%
TVTX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.13
$1.97
-$1.18
-$1.76
-
Expected
-$1.14
-$0.14
-$1.27
-$0.99
-$0.89
Surprise
-0.95%
-1,480.26%
-7.27%
77.61%
-
TVTX News
AllArticlesVideos
Travere Therapeutics to Report Second Quarter 2024 Financial Results
GlobeNewsWire·1 day ago
Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
GlobeNewsWire·3 weeks ago
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Travere Therapeutics stock?
Travere Therapeutics (TVTX) has a market cap of $744M as of July 27, 2024.
What is the P/E ratio for Travere Therapeutics stock?
The price to earnings (P/E) ratio for Travere Therapeutics (TVTX) stock is 0 as of July 27, 2024.
Does Travere Therapeutics stock pay dividends?
No, Travere Therapeutics (TVTX) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Travere Therapeutics dividend payment date?
Travere Therapeutics (TVTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Travere Therapeutics?
Travere Therapeutics (TVTX) has a beta rating of 0.78. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Travere Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.